Trevi Therapeutics Capital Expenditures (CapEx) Growth & History (TRVI)

Trevi Therapeutics's capital expenditures (capex) was $12,000 for fiscal 2025.

View full Trevi Therapeutics company overview

Trevi Therapeutics annual capital expenditures (capex) history

Trevi Therapeutics annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20252025-12-31$12,000−$23,000−65.71%
20242024-12-31$35,000−$102,000−74.45%
20232023-12-31$137,000−$22,000−13.84%
20222022-12-31$159,000
20202020-12-31$32,000$23,000+255.56%
20192019-12-31$9,000−$149,000−94.30%
20182018-12-31$158,000

Trevi Therapeutics capital expenditures (capex) trends

Over the last five fiscal years, Trevi Therapeutics's capital expenditures (capex) decreased from $32,000 to $12,000, a change of −$20,000. The latest reported quarter, Q2 2026, shows $124,000.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

SEC-reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Trevi Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about TRVI yet. Start the conversation.

Write the first post